BRUSSELS: UCB, a global biopharmaceutical company, announced Tuesday it has signed a definitive agreement to acquire Candid Therapeutics, a privately held clinical-stage biotechnology company developing novel T-cell engagers (TCEs) for autoimmune and inflammatory diseases.
Under the terms of the agreement, UCB will pay $2 billion upfront, with an additional $200 million in potential future milestone payments. The transaction is expected to close by the end of the second quarter or early third quarter of 2026, subject to antitrust clearance and other customary conditions.
The acquisition centers on cizutamig, Candid’s lead investigational asset, which UCB described as a potential best-in-class BCMA TCE for autoimmune diseases. The bispecific antibody targets BCMA on plasma cells and CD3 on T-cells, enabling T-cell-mediated cytotoxicity against BCMA-expressing plasma cells and B-cells. Designed to maintain cytotoxicity while limiting cytokine release, cizutamig has been evaluated in more than 100 patients with multiple myeloma and autoimmune diseases and is currently in multiple clinical studies across more than 10 autoimmune indications.
“This acquisition demonstrates our inorganic innovation strategy in action and marks a pivotal moment for UCB, as we secure a significant technological advancement in the field with the addition of cizutamig to our pipeline,” said Jean-Christophe Tellier, CEO of UCB. “This exemplifies the next wave of therapies to treat immune-mediated diseases and reflects our commitment to setting new standards to achieve immune reset.”
The deal builds on UCB’s recently announced transaction with Antengene and reflects a platform-driven strategy in next-generation immunology. Beyond cizutamig, Candid is developing a pipeline of multi-specific TCE antibodies designed to enable deep, targeted depletion of pathogenic B-cell populations.
“We started Candid with the goal to redefine the standard of care for immune-mediated diseases,” said Dr. Ken Song, chairman, CEO and president of Candid Therapeutics. “UCB’s successful track record in immunology, including development, launch, and commercialization, will enable the continuation of our clinical programs and help deliver on the potential for our pipeline.”
Lazard is acting as financial advisor to UCB, with Covington & Burling LLP serving as legal counsel. Jefferies LLC and Goldman Sachs & Co. LLC are acting as joint lead financial advisors to Candid, with BofA Securities Inc. also providing financial advice. Cooley LLP is serving as legal counsel to Candid.
Cizutamig is an investigational drug and has not been approved by the FDA or other health authorities.
Editor’s Commentary: Let’s be honest: $2.2 billion for a company founded in 2024 with no approved products is the kind of headline that makes you check the date. But here’s why this one isn’t crazy.
UCB isn’t buying a hope and a prayer. They’re buying data — over 100 patients’ worth across multiple myeloma and autoimmune diseases, plus an ongoing presence in more than 10 autoimmune indications. That’s not a slide deck; that’s a running start.
The smarter read here is platform over product. UCB isn’t just acquiring cizutamig; they’re buying a modular, multi-antigen targeting strategy that pairs with their Antengene deal. That’s a hedge against the classic biotech risk of a single asset flaming out in Phase 3. Spread the bets across B-cell targets, stack the mechanisms, and suddenly “immune reset” sounds less like marketing and more like a roadmap.
The CEO quote about “inorganic innovation strategy” is peak pharma-speak, but the math checks out. UCB posted €7.7 billion in revenue for 2025. A $2 billion upfront is a meaningful bet — roughly a quarter of their annual revenue — but not a reckless one. And the relatively modest $200 million in milestones suggests the heavy lifting on proof-of-concept is already done.
What’s missing? The FDA’s voice. Cizutamig hasn’t been approved anywhere, and cytokine release syndrome has humbled bigger TCE programs than this one. The design sounds elegant on paper. Biology has a way of ignoring paper.
Still, for patients with severe, underserved autoimmune diseases — the ones who have cycled through every biologic on the market — a TCE that deeply depletes pathogenic B-cells without laying waste to the rest of the immune system would be nothing short of transformative. UCB is paying $2.2 billion to find out if that’s possible. That’s not irrational. That’s the price of finding out before your competitor does.